Regenxbio Inc
(NAS:RGNX)
$
7.41
-0.46 (-5.84%)
Market Cap: 367.13 Mil
Enterprise Value: 218.52 Mil
PE Ratio: 0
PB Ratio: 1.22
GF Score: 65/100 Regenxbio Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021 / 03:00PM GMT
Release Date Price:
$33.54
(-2.27%)
Esther P. Rajavelu
UBS Investment Bank, Research Division - Analyst & Executive Director
Good morning, everyone, and thank you for joining us at the UBS Virtual Healthcare Conference Day 2.
I'm excited to have the REGENX management team here with us for a fireside chat, and we're joined by REGENX Chief Medical Officer, Steve Pakola; and Chief Scientific Officer, Olivier Danos.
Gentlemen, welcome, and thank you for making time for us.
Stephen Pakola
REGENXBIO Inc. - Senior VP & Chief Medical Officer
Good morning Esther. Thanks for the invitation. We're glad to be with -- here with you.
Olivier Danos
REGENXBIO Inc. - Senior VP & Chief Scientific Officer
Good morning.
Esther P. Rajavelu
UBS Investment Bank, Research Division - Analyst & Executive Director
And I apologize for not being on camera. We've had some technical difficulty. But perhaps, Steve, maybe you can start us off with what's on tap for the rest of the year and give us
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot